A GOOD IDEA DOESN'T NECESSARILY MAKE FOR A BETTER PIPELINE

News

Pharmaceutical companies invest billions in research and development. However, high R&D spending alone does not guarantee a more productive pipeline. What matters is how ideas are prioritized, decisions are made, and initiatives are translated into action.

 

In a recent online article published by Handelsblatt, Dr. Alexander Tarlatt and Ravi Chugh explain why isolated efficiency improvements are not enough and why research and development in the pharmaceutical industry must be viewed as an integrated system.

 

With its “Pipeline Success Engine,” Santiago Advisors pursues an approach that brings strategy, portfolio decisions, and execution closer together. Find out how companies can strengthen their innovation capabilities and turn promising ideas into tangible progress more quickly in the full article here.

Your direct contact at Santiago

Dr. Alexander Tarlatt
Managing Director